The interesting thing to me about that PR from Cyto is no mention of PSMA Development company, the 50/50 JV with Progenics that I thought held great promise for developing PSMA based drugs. But ever since the partnership was announced, virtually no public progress has been made. The PSMA based product described in this PR is a logical outgrowth of Cyto's current pipeline. I think it sounds like a promising approach.
Market Data 
Markets 
AI
